FDA approval for Lilly’s Bydureon delayed until Jan 28
Subsequent to a delay of one year for the approval of once-per-week diabetes drug Bydureon, the United States Food and
Read moreamylin
Amylin, Takeda discontinue development of obesity treatment
Earlier on Thursday, Takeda Pharmaceutical Co. Ltd and Amylin Pharmaceuticals Inc. announced the discontinuation of the development of their combination
Read moreAs Expenses Plummet, Amylin Pharma Narrows 2Q Losses
Earlier on Tuesday, Amylin Pharmaceuticals Inc. announced the narrowing of its losses in the second-quarter as the decline in costs
Read more